甲状腺相关眼病(TAO)位居成人致盲性眼眶疾病之首,然而,目前仍未清楚其发病机制。在TAO的临床治疗方面,除了一些经典的糖皮质激素方案,新型的联合治疗方案、药物、外科手段等经过一定临床验证后也正逐渐被临床工作者和患者接受。 Thyroid-associated ophthalmopathy (TAO) is the leading cause of blinding orbital diseases in adults, however, its pathogenesis is still unclear. TAO clinical treatment, in addition to some of the classic glucocorticoid program, a new combination of treatment programs, drugs, surgical methods, after some clinical validation is also gradually accepted by clinicians and patients.